Nicola Wealth Management LTD. Acquires 59,000 Shares of Perrigo Company plc (NYSE:PRGO)

Nicola Wealth Management LTD. increased its stake in shares of Perrigo Company plc (NYSE:PRGO) by 59.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,000 shares of the company’s stock after buying an additional 59,000 shares during the quarter. Nicola Wealth Management LTD.’s holdings in Perrigo were worth $4,171,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PRGO. Dimensional Fund Advisors LP raised its position in Perrigo by 3.6% during the second quarter. Dimensional Fund Advisors LP now owns 7,162,656 shares of the company’s stock valued at $183,935,000 after purchasing an additional 249,640 shares in the last quarter. Deprince Race & Zollo Inc. boosted its stake in Perrigo by 11.2% in the second quarter. Deprince Race & Zollo Inc. now owns 3,882,438 shares of the company’s stock valued at $99,701,000 after buying an additional 391,646 shares in the last quarter. Cooke & Bieler LP grew its position in Perrigo by 0.9% in the second quarter. Cooke & Bieler LP now owns 3,501,401 shares of the company’s stock valued at $89,916,000 after acquiring an additional 30,150 shares during the last quarter. Copeland Capital Management LLC lifted its holdings in shares of Perrigo by 23.1% in the third quarter. Copeland Capital Management LLC now owns 2,482,544 shares of the company’s stock worth $65,117,000 after acquiring an additional 465,161 shares during the last quarter. Finally, Sound Shore Management Inc. CT grew its position in Perrigo by 5.2% during the 2nd quarter. Sound Shore Management Inc. CT now owns 2,391,049 shares of the company’s stock worth $61,402,000 after acquiring an additional 117,230 shares during the last quarter. 95.91% of the stock is owned by institutional investors.

Perrigo Trading Down 1.2 %

Shares of PRGO stock traded down $0.32 on Thursday, hitting $26.49. 174,863 shares of the company’s stock traded hands, compared to its average volume of 1,620,248. The company’s fifty day simple moving average is $26.01 and its 200 day simple moving average is $27.37. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. Perrigo Company plc has a one year low of $23.89 and a one year high of $34.60. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -22.91 and a beta of 0.48.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, November 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.81. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the company earned $0.64 EPS. The business’s revenue was down 3.2% compared to the same quarter last year. Equities analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 17th. Stockholders of record on Friday, November 29th will be issued a dividend of $0.276 per share. This represents a $1.10 dividend on an annualized basis and a dividend yield of 4.17%. The ex-dividend date of this dividend is Friday, November 29th. Perrigo’s payout ratio is presently -94.02%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 price objective (down previously from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $42.00 target price on shares of Perrigo in a research report on Monday, September 30th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.00.

Insider Activity

In other Perrigo news, EVP Ronald Craig Janish sold 13,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $29.40, for a total transaction of $382,200.00. Following the completion of the sale, the executive vice president now directly owns 20,553 shares in the company, valued at $604,258.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Katherine C. Doyle sold 8,954 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $27.30, for a total transaction of $244,444.20. Following the transaction, the director now owns 6,009 shares in the company, valued at approximately $164,045.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Ronald Craig Janish sold 13,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $29.40, for a total transaction of $382,200.00. Following the transaction, the executive vice president now owns 20,553 shares in the company, valued at approximately $604,258.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,254 shares of company stock valued at $1,411,969 over the last three months. Insiders own 0.70% of the company’s stock.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.